Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2024-10-11 Share Issue/Capital Cha…
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement dated October 11, 2024, titled 'Pharma Equity Group announces successful completion of directed issue of new shares.' It explicitly details the completion of a capital increase, the resulting new total share capital (DKK 122,755,665.9), and the total number of voting rights. This content directly relates to changes in the company's capital structure due to the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release, an annual report, or a mere announcement of a report publication.
2024-10-11 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 98% confidence The document text is a formal announcement titled 'Pharma Equity Group offentliggør succesfuld gennemførsel af rettet emission' (Pharma Equity Group announces successful completion of directed issue). It details the completion of a capital increase ('kapitalforhøjelsen'), the resulting change in share capital ('aktiekapital'), and the total number of voting rights. This content directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it mentions a registration with the Business Authority ('Erhvervsstyrelsen'), the core subject is the successful completion of the share issuance/financing event, not a general regulatory filing (RNS) or a report announcement (RPA). The document length (3326 chars) is substantial enough to be the primary announcement, not just a placeholder.
2024-10-11 Danish
Pharma Equity Group announces successful completion of directed issue of new shares
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Pharma Equity Group regarding the completion of a directed share issue (rettet emission) and the subsequent registration of the capital increase with the Danish Business Authority (Erhvervsstyrelsen). It details the number of new shares issued, the nominal value, the total share capital, and the total number of voting rights. This falls squarely under the category of share issuance and capital changes.
2024-10-11 Danish
Pharma Equity Group announces successful completion of directed issue of new shares
Share Issue/Capital Change Classification · 100% confidence The document announces the successful completion of a directed share issue and the registration of a capital increase with the Danish Business Authority. It details the number of new shares, the price per share, and the resulting total share capital and voting rights. This falls directly under the definition of a share issue or capital change announcement.
2024-10-11 Danish
Capital/Financing Update 2024
Capital/Financing Update Classification · 98% confidence The document is a formal announcement from 'Pharma Equity Group A/S' dated October 4, 2024, detailing the decision to issue new shares through a directed share issue ('rettet emission') to raise capital (DKK 51,148,194). It explicitly mentions the increase in share capital, the subscription price, the conversion of convertible debt, and the expected registration date with the Danish Business Authority ('Erhvervsstyrelsen'). This content directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (4737 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2024-10-04 Danish
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 99% confidence The document is titled "Pharma Equity Group announces issuance of new shares in a direct issue" and details the resolution by the board of directors to issue 204,592,776 new shares for cash proceeds, including the conversion of convertible debt. This action directly relates to changing the company's capital structure through the issuance of new equity. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital transaction.
2024-10-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.